[1] Belli LS, Duvoux C, Berenguer M, et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol, 2017, 67: 585-602.
[2] Pascasio JM, Vinaixa C, Ferrer MT, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol, 2017, Aug 24. pii: S0168-8278(17)32215-8. doi: 10.1016/j. jhep.2017.08.008. [Epub ahead of print].
[3] Chhatwal J, Samur S, Kues B, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology, 2017, 65: 777-788.
[4] Levitsky J, Verna EC, O'Leary JG, et al. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients. N Engl J Med, 2016, 375: 2106-2108. |
